|Table of Contents|

Relationship between the number of peripheral blood CD8+T lymphocytes and postoperative disease-free survival in patients with stage Ⅲ colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 07
Page:
1278-1282
Research Field:
Publishing date:

Info

Title:
Relationship between the number of peripheral blood CD8+T lymphocytes and postoperative disease-free survival in patients with stage Ⅲ colorectal cancer
Author(s):
DONG Jiuxing1; ZHAO Jia2; AN Yanchun2; XIONG Luning1; CHEN Yue1; REN Jiyong1; WANG Qianjin1; GENG Ling1
1.Oncology Department;2.Emergency Department,Hebei Petro China Central Hospital,Hebei Langfang 065000,China.
Keywords:
CD8+T lymphocytes; colorectal cancer; tumor prognosis; risk factors; survival analysis
PACS:
R735.3+5
DOI:
10.3969/j.issn.1672-4992.2024.07.016
Abstract:
Objective:To explore the relationship between the number of CD8+T lymphocytes in peripheral blood and disease-free survival(DFS) in colorectal cancer(CRC) patients.Methods:81 patients with stage Ⅲ CRC in the clinical stage of Hebei Petro China Central Hospital from 1st Juanuary,2019 to 31st,December,2021 were selected as the study subjects,and the number of peripheral blood CD8+T lymph number at the three nodes of preoperative,postoperative first adjuvant chemotherapy and end of treatment was monitored,the clinical and pathological data of the enrolled patients were counted.All enrolled patients were followed up until 31st,December,2022,and the patient's operation time,time of local recurrence or distant metastasis or death time were recorded.The binary logistic regression model was used for multivariate analysis to screen the independent risk factors for tumor progression in the enrolled patients.The patients were grouped according to the characteristics of the change of CD8+T lymph number in the three nodes of the enrolled patients,and the survival curves of each group were plotted by Kaplan-Meier method.Results:Multivariate analysis showed that pT4(OR=11.647,95%CI was 2.255~60.166,P=0.003),CEA value(OR=1.044,95%CI was 1.010~1.079,P=0.011) were independently correlated with postoperative tumor progression and were independent risk factors for enrolled patients.The number of CD8+T lymphocytes(OR=0.973,95%CI was 0.951~0.997,P=0.025) before the first postoperative adjuvant chemotherapy was an independent protective factor screened by multiple factors.The enrolled patients were grouped according to the characteristics of monitoring the change of CD8+T lymph number at three nodes，survival analysis of each group was shown：The median disease-free survival(mDFS) of the patients with persistently elevated CD8+T lymphocyte numbers(group I) was not reached.The mDFS of the patients with the number of CD8+T lymphocytes increased first,and then decreased(group Ⅱ) was(28.9±2.7)months,95%CI was 23.6~34.2 months.The mDFS of the patients with the number of CD8+T lymphocytes decreased first,and then increased(group Ⅲ) was(27.2±2.2)months,95%CI was 22.9~31.5 months.The mDFS of the patients with the number of CD8+T lymphocytes continued decline(group IV) was(22.8±3.5)months,95%CI 15.9~29.7 months.There was no statistical difference in mDFS in group Ⅱ,group Ⅲ and group IV,and there was a statistical difference between mDFS in group I and other three groups,and Log-rank P=0.026.Conclusion:The higher the number of CD8+T lymphocytes before the first adjuvant chemotherapy after surgery in patients with stage Ⅲ CRC,the longer the DFS and the better the prognosis.The number of CD8+T lymphocytes was dynamically monitored throughout the treatment of patients with stage Ⅲ CRC,and DFS in patients with continuously elevated CD8+T lymphocytes was significantly better than that of other patients.

References:

[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2]CARLSSON U,LASSON A,EKELUND G.Recurrence rates after curative surgery for rectal carcinoma,with special reference to their accuracy［J］.Disease of Colon and Rectum,1987,30(6):431-434.
[3]DEKKER E,TANIS PJ,VLEUGELS JLA,et al.Colorectal cancer［J］.Lancet,2019,394(10207):1467-1480.
[4]OSTERMAN E,HAMMARSTROM K,IMAM I,et al.Recurrence risk after radical colorectal cancer surgery-less than before,but how high is it［J］.Cancers(Basel),2020,12(11):3308-3338.
[5]GONG XL,ZHAO L.Immune checkpoint inhibitors in the treatment of colorectal cancer:a review of clinical trials［J］.Chinese Journal of Surgery,2022,25(3):205-213.
[6]GHIDINI M,FUSCO N,SALATI M,et al.The emergence of immune-checkpoint inhibitors in colorectal cancer therapy［J］.Current Drug Targets,2021,22(9):1021-1033.
[7]RUI R,ZHOU L,HE S.Cancer immunotherapies:advances and bottlenecks［J］.Frontiers Immunology,2023,14:1212476.
[8]LI L,XIE CHY,ZHENG MY,et al.Advances in research on tumor immunotherapy［J］.Chinese Journal of Nature,2021,43(6):391-399.
[9]LIU Y,ZHOU N,ZHOU L,et al.IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor［J］.Nature Immunology,2021,22(3):358-369.
[10]BRUNI D,ANGELL HK,GALON J.The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy［J］.Nature Reviews Cancer,2020,20(11):662-680.
[11]MUNARI E,MARCONI M,QUERZOLI G,et al.Impact of PD-L1 and PD-1 expression on the prognostic significance of CD8+ tumor-infiltrating lymphocytes in non-small cell lung cancer［J］.Frontiers in Immunology,2021,12:680973.
[12]刘畅,王红艳.CD8+ T细胞活化与分化的分子机制［J］.中国免疫学杂志,2017,33(4):481-487. LIU C,WANG HY.Molecular mechanism of CD8+ T cell activation and differentiation［J］.Chinese Journal of Immunology,2017,33(4):481-487.
[13]GARCIA P,HARTMAN D,CHOUDRY H,et al.CD8+ T-cell density is an independent predictor of survival and response to adjuvant chemotherapy in stage III colon cancer［J］.Applied Immunohistochemistry & Molecular Morphology,2023,31(2):69-73.
[14]KATAYAMA C,YOKOBORI T,OZAWA N,et al.Low level of stromal lectin-like oxidized LDL receptor 1 and CD8+ cytotoxic T-lymphocytes indicate poor prognosis of colorectal cancer［J］.Cancer Reports,2021,4(4):e1364.
[15]张泉,邱思芳,赵逵,等.结直肠癌及腺瘤患者CD4+、CD8+和CD28+T淋巴细胞的亚群变化及临床意义［J］.中国癌症杂志,2018,28(8):577-583. ZHANG Q,QIU SF,ZHAO K,et al.Subsets and clinical significance of CD4+,CD8+ and CD28+ T lymphocytes in the patients with colorectal carcinoma and adenoma［J］.China Oncology,2018,28(8):577-583.
[16]IDOS GE,KWOK J,BONTHALA N,et al.The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer:A systematic review and Meta-analysis［J］.Scientific Reports,2020,10(1):3360.
[17]LI X,WEN D,LI X,et al.Identification of an immune signature predicting prognosis risk and lymphocyte infiltration in colon cancer［J］.Frontiersin Immunology,2020,3(11):1678.
[18]MILLER TJ,ANYAEGBU CC,LEE-PULLEN TF,et al.PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer［J］.Cancer Science,2021,112(3):1173-1183.
[19]YANG L,ZHANG X,HUANG X,et al.Correlation between IFNAR1 expression in peripheral blood T lymphocytes and inflammatory cytokines,tumor-infiltrating lymphocytes,and chemosensitivity in patients with colorectal cancer［J］.Cytokine,2022,159:156008.
[20]WAIDHAUSER J,NERLINGER P,ARNDT TT,et al.Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma［J］.Cancer Immunol Immunother,2022,71(8):1937-1947.
[21]钟国方,张航,袁霞.微卫星状态与结直肠癌临床病理特征、外周血T细胞及基因突变的关系［J］.广东医科大学学报,2021,39(5):557-561. ZHONG GF,ZHANG H,YUAN X.Relationship between microsatellite status and clinicopathological features,peripheral blood T cells and gene mutations in colorectal cancer［J］.Journal of Guangdong Medical University,2021,39(5):557-561.
[22]陈志冰,陈英云,王祥谷.外周血T淋巴细胞水平与结直肠癌腹腔镜根治术后复发的相关性分析［J］.微创医学,2022,17(01):111-114. CHEN ZB,CHEN YY,WANG XG.Correlation analysis of peripheral blood T lymphocyte levels and recurrence after laparoscopic radical resection for colorectal cancer［J］.Journal of Minimally Invasive Medicine,2022,17(01):111-114.
[23]YOU K,PARK HC,PARK SC,et al.Laparoscopic approach for T4 colon cancer can be associated with poor prognosis in right-sided T4b tumours［J］.European Journal of Surgical Oncology,2021,47(7):1645-1650.
[24]COMPTON CC,FIELDING LP,BURGART LJ,et al.Prognostic factors in colorectal cancer.College of American Pathologists Consensus Statement 1999［J］.Archives of Pathology & Laboratory Medicine,2000,124(7):979-994.
[25]CARRIQUIRY LA,PINEYRO A.Should carcinoembryonic antigen be used in the management of patients with colorectal cancer［J］.Diseases of the Colon & Rectum,1999,42(7):921-929.
[26]中国医师协会外科医师分会,中华医学会外科分会胃肠外科学组,中华医学会外科分会结直肠外科学组,等.中国结直肠癌肝转移诊断和综合治疗指南(V2023)［J］.中华胃肠外科杂志,2023,26(1):1-15. Chinese College of Surgeons,Section of Gastrointestinal Surgery,Branch of Surgery,Chinese Medical Association,Section of Colorectal Surgery,Branch of Surgery,Chinese Medical Association,et al.China guideline for diagnosis and comprehensive treatment of colorectal liver metastases(version 2023)［J］.Chinese Journal of Surgery,2023,26(1):1-15.

Memo

Memo:
河北省廊坊市科技支撑计划项目（编号：2021013038）
Last Update: 2024-02-29